Sin embargo, la cantidad de L-Carnitina que se obtiene de los alimentos no siempre es suficiente para obtener los beneficios que ofrece este suplemento
Monitoring Timeline Summary | Timepoint | Action | |---|---| | Baseline | Weight, BMI, waist, HbA1c, fasting glucose, lipids, LFTs, CMP, hepatic imaging if MASLD suspected | | Week 4 (end of 2 mg step) | Weight, tolerability assessment, GI symptom score | | Week 8 (end of 4 mg step) | Weight, fasting glucose, LFTs | | Week 12 (end of first 8 mg step) | Full metabolic panel, INR if on warfarin, thyroid function if indicated | | Week 24 (end of titration) | Full panel, hepatic imaging for MASLD, 5% weight-loss response assessment | | Every 12 weeks at maintenance | Weight, HbA1c or fasting glucose, lipids, LFTs, CMP | | At each taper step | Weight, fasting glucose (daily self-monitoring for T2D patients) | Frequently asked questions What is the triple agonist drug class
And what makes it so special
doi: 10.1007/s00394-004-0461-7 14
Get in touch with us right now